Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obesity and Weight Loss.

European cardiology·2019
Same author

Non-PCI/CABG therapies for refractory angina.

Trends in cardiovascular medicine·2017
Same author

Prognostic Significance of Asymptomatic Myocardial Ischemia in Women vs. Men.

Current pharmaceutical design·2016
Same author

Coronary Artery Calcium Scanning: Past, Present, and Future.

JACC. Cardiovascular imaging·2016
Same author

Editorial Commentary: Statins and acute coronary syndromes.

Trends in cardiovascular medicine·2016
Same author

Ranolazine in Cardiac Arrhythmia.

Clinical cardiology·2015
Same journal

Real-World National Databases Versus Hypothesis-Driven Cohort Studies: A Reply to the Critique on the TURK-HF Registry Design.

Clinical cardiology·2026
Same journal

Comment on Wang et al.: Unaddressed Multiple Comparisons Risk Inflating Type, Error in Cardiovascular Specialty Nursing Research.

Clinical cardiology·2026
Same journal

Methodological and Statistical Confounding in Comparing Patient-Reported Outcomes Between Cardioversion and Ablation for Atrial Fibrillation.

Clinical cardiology·2026
Same journal

In-Hospital Cardiac Arrest Detection Performance Analysis and Comparison on Effective Feature Selection.

Clinical cardiology·2026
Same journal

Interpreting the Association Between Diuretic Intensity Score and Mortality: The Potential Roles of Diuretic Responsiveness and Mineralocorticoid Receptor Antagonist Therapy.

Clinical cardiology·2026
Same journal

Heart Failure With Preserved Ejection Fraction-Like Phenotype in Coronary Artery Disease and Obstructive Sleep Apnea: Insights From the RICCADSA Cohort.

Clinical cardiology·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antiplatelets and anticoagulants.

C Richard Conti

    Clinical Cardiology
    |July 20, 2010
    PubMed
    Summary
    This summary is machine-generated.

    This editorial reviews common antiplatelet and anticoagulant medications like aspirin, clopidogrel, and warfarin used for cardiovascular disorders. It also discusses less common and emerging clinical drugs for managing these conditions.

    More Related Videos

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
    10:28

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

    Published on: March 15, 2022

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
    09:13

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

    Published on: April 6, 2017

    Related Experiment Videos

    Last Updated: Jun 10, 2026

    Ferric Chloride-induced Murine Thrombosis Models
    10:37

    Ferric Chloride-induced Murine Thrombosis Models

    Published on: September 5, 2016

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
    10:28

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

    Published on: March 15, 2022

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
    09:13

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

    Published on: April 6, 2017

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Cardiovascular disorders frequently necessitate the use of antiplatelet and anticoagulant therapies.
    • Commonly prescribed agents include aspirin, clopidogrel, and warfarin.

    Discussion:

    • This editorial offers a personal perspective on the clinical utility of established and novel antithrombotic agents.
    • It covers drugs currently in widespread use, those with less frequent application, and those anticipated for future clinical integration.

    Key Insights:

    • Aspirin, clopidogrel, and warfarin represent cornerstone therapies in managing thrombotic risk.
    • The landscape of antithrombotic pharmacotherapy is evolving, with new agents offering potential therapeutic advancements.

    Outlook:

    • Future clinical practice may incorporate a broader spectrum of antiplatelet and anticoagulant drugs.
    • Personalized medicine approaches will likely guide the selection of antithrombotic agents based on individual patient profiles and risk factors.